HEALTHCARE

Market Highlights: The Global Myelodysplastic Syndrome (MDS) Drugs Market is expected to grow significantly over the forecast period. The Myelodysplastic Syndrome (MDS) drugs market held a valuation of USD 1,581.59 million in 2018 and is projected to register a CAGR of 10.1% over the forecast period. The increasing participation of key players is one of the key factors driving the  Myelodysplastic Syndrome (MDS) drugs  market. In 2018, the US Food and Drug Administration approved generic injectable product decitabine for Lupin Ltd. There are various other MDS medications available in the market. Various other factors that are driving the MDS drugs market are the promotion of clinical studies related to MDS, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drugs manufactures. However, the risk of infections during blood transfusions and side-effects of chemotherapy may hamper market growth over the forecast pe...